1. Home
  2. NCNO vs NVAX Comparison

NCNO vs NVAX Comparison

Compare NCNO & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NCNO

nCino Inc.

HOLD

Current Price

$17.76

Market Cap

1.6B

Sector

Technology

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$9.58

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCNO
NVAX
Founded
2011
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
2022
1996

Fundamental Metrics

Financial Performance
Metric
NCNO
NVAX
Price
$17.76
$9.58
Analyst Decision
Buy
Hold
Analyst Count
16
9
Target Price
$26.07
$11.33
AVG Volume (30 Days)
3.9M
4.4M
Earning Date
05-27-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
115.15
309.76
EPS
0.12
N/A
Revenue
$594,781,000.00
$1,123,479,000.00
Revenue This Year
$9.53
N/A
Revenue Next Year
$8.97
N/A
P/E Ratio
$147.92
N/A
Revenue Growth
10.01
64.69
52 Week Low
$13.80
$6.20
52 Week High
$33.92
$11.85

Technical Indicators

Market Signals
Indicator
NCNO
NVAX
Relative Strength Index (RSI) 66.08 56.88
Support Level $14.04 $7.99
Resistance Level $18.65 $10.09
Average True Range (ATR) 0.89 0.56
MACD 0.35 0.06
Stochastic Oscillator 90.91 79.73

Price Performance

Historical Comparison
NCNO
NVAX

About NCNO nCino Inc.

Ncino Inc is a provider of cloud-based software for financial institutions. It is focused on developing the nCino Platform to transform commercial and small business lending for community and regional banks in the U.S. With the company's platform financial institutions can Operate More Intelligently, Improve Efficiency, Elevate Employee and Client Experiences, and Manage Risk and Compliance Continuously Rather Than Reactively. It has built and acquired technology, including SimpleNexus, DocFox, FullCircl, ILT, Visible Equity, FinSuite, and Sandbox Banking, to augment the nCino Platform's capabilities for mortgage lending, onboarding, account opening, indirect auto lending, and analytics and AI. The company operates as one operating segment.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: